A DOUBLE-BLIND, MULTICENTER COMPARISON OF 0.05-PERCENT HALOBETASOL PROPIONATE OINTMENT AND 0.05-PERCENT CLOBETASOL PROPIONATE OINTMENT IN PATIENTS WITH CHRONIC, LOCALIZED PLAQUE PSORIASIS

被引：27

作者：

GOLDBERG, B ^{[1
]}

HARTDEGEN, R ^{[1
]}

PRESBURY, D ^{[1
]}

SMITH, EH ^{[1
]}

YAWALKAR, S ^{[1
]}

机构：

[1] CIBA GEIGY AG,CH-4002 BASEL,SWITZERLAND

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 1991年 / 25卷 / 06期

关键词：

D O I：

10.1016/0190-9622(91)70313-Q

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

In a double-blind, parallel-group, multicenter trial in 134 patients with severe, localized, plaque psoriasis, the success rate (described as "healed" or "marked improvement") at the end of the study was 96% in the halobetasol propionate group and 91% in the clobetasol propionate group. A significantly larger proportion of patients treated with halobetasol had no disease or mild disease after 14 days compared with those treated with clobetasol (86% versus 70%, p = 0.023). Healing within 24 days of starting treatment was noted in 69% and 56% of patients treated with halobetasol and clobetasol, respectively. Adverse effects were reported in a smaller percentage of patients treated with halobetasol propionate ointment than in those treated with clobetasol propionate ointment (7% versus 12%). Cosmetic acceptability and ease of application were recorded as "very good" in a larger percentage of patients treated with halobetasol propionate ointment than in the group treated with clobetasol propionate (90% versus 80%).

引用

页码：1145 / 1148

页数：4